The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwAL 2026 | Combining differentiation therapy with BCL2 inhibition: impact on the DS risk profile
Stéphane De Botton, MD, PhD, Gustave Roussy Institute, Paris, France, discusses the potential impact of combining differentiation therapy with BCL2 inhibition on the differentiation syndrome (DS) risk profile, noting that combining venetoclax with menin or IDH inhibitors may reduce the incidence of DS due to the cytotoxic effects of venetoclax on blast cells. This interview took place at the 8th International Workshop on Acute Leukemias (iwAL 2026), held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have flavors that combining venetoclax plus menin or plus IDH inhibitors reduced the incidence of the syndromes. It’s based on the fact that ven-aza is truly cytotoxic and if you eliminate the cause of the DS, meaning blast cells, you see the reduction of DS syndrome that has been shown, especially with the triplet with IDH1 inhibitor or IDH2 inhibitor.
This transcript is AI-generated...
We have flavors that combining venetoclax plus menin or plus IDH inhibitors reduced the incidence of the syndromes. It’s based on the fact that ven-aza is truly cytotoxic and if you eliminate the cause of the DS, meaning blast cells, you see the reduction of DS syndrome that has been shown, especially with the triplet with IDH1 inhibitor or IDH2 inhibitor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
